<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611114</url>
  </required_header>
  <id_info>
    <org_study_id>BIOSCI 15-030</org_study_id>
    <nct_id>NCT03611114</nct_id>
  </id_info>
  <brief_title>The Impact of Citrus Products on Cardiovascular Health</brief_title>
  <official_title>Effects of Blood Orange Juice Consumption on Endothelial Function in Healthy Overweight/Obese Men and Premenopausal Women of European Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidemiological studies have indicated that the consumption of citrus fruit is inversely
      associated with the risk of cardiovascular disease. However, clinical data regarding the
      effects of blood orange juice upon endothelial function is scarce. This randomised, crossover
      study investigates whether blood orange juice compared to a control drink improves blood
      vessel function and other cardiovascular health indicators (such as blood pressure and blood
      lipids). All the subjects will be asked to consume blood orange juice and a control drink in
      a randomised order, each over a 2-week period, divided by a 1-week wash out period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endothelial function measured via flow mediated dilation (FMD), blood pressure,
      anthropometric measures, lipid profile, high-sensitivity C-reactive protein (hsCRP) and
      endothelin 1 (ET-1), cyclic guanosine monophosphate (cGMP) will be evaluated in healthy
      overweight/obese Caucasians prior to and following 2-week consumption of blood orange juice
      and a control drink. Evaluation of endothelial function as measured by FMD will be conducted
      on specific days of the menstrual cycle to minimise the fluctuation in oestrogen levels in
      premenopausal women, which will be monitored in serum samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Actual">August 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 21, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in flow mediated dilation between baseline and endpoint within the intervention group vs. control group</measure>
    <time_frame>Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.</time_frame>
    <description>FMD will be evaluated prior to and following 2-week consumption of either blood orange juice or a control drink.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure between baseline and endpoint within the intervention group vs. control group</measure>
    <time_frame>Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.</time_frame>
    <description>Blood pressure will be measured prior to and following 2-week consumption of either blood orange juice or a control drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lipid profile between baseline and endpoint within the intervention group vs. control group</measure>
    <time_frame>Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.</time_frame>
    <description>Serum total cholesterol, HDL cholesterol, LDL cholesterol will be measured prior to and following 2-week consumption of either blood orange juice or a control drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in high sensitivity Câ€‘reactive protein between baseline and endpoint within the intervention group vs. control group</measure>
    <time_frame>Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.</time_frame>
    <description>Serum hsCRP will be measured prior to and following 2-week consumption of either blood orange juice or a control drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in endothelin-1 (ET-1) between baseline and endpoint within the intervention group vs. control group</measure>
    <time_frame>Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.</time_frame>
    <description>Serum ET-1 will be measured prior to and following 2-week consumption of either blood orange juice or a control drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in oestradiol between baseline and endpoint within the intervention group vs. control group</measure>
    <time_frame>Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.</time_frame>
    <description>Serum oestradiol will be measured prior to and following 2-week consumption of either blood orange juice or a control drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in flavanone metabolites between baseline and endpoint within the intervention group vs. control group</measure>
    <time_frame>Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.</time_frame>
    <description>Flavanone metabolites will be measured prior to and following 2-week consumption of either blood orange juice or a control drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cyclic guanosine monophosphate (cGMP) between baseline and endpoint within the intervention group vs. control group</measure>
    <time_frame>Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.</time_frame>
    <description>Cyclic guanosine monophosphate (cGMP) will be measured prior to and following 2-week consumption of either blood orange juice or a control drink.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Blood orange juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be asked to consume blood orange juice (400 ml/day) for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be asked to consume a control drink (400 ml/day) for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blood orange juice</intervention_name>
    <arm_group_label>Blood orange juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control drink</intervention_name>
    <arm_group_label>Control drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy

          -  Caucasians (of European origin)

          -  BMI &gt; 25 kg/m2

        Exclusion Criteria:

          -  Presence of cardiovascular diseases

          -  Smoking

          -  Use of medications or dietary supplements (vitamins, antioxidants)

          -  On a special diet and/or a training program to change weight
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lu Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leeds</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen M Birch, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Leeds</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Bosch, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Leeds</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Leeds</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9JT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Muller-Delp JM, Lubahn DB, Nichol KE, Philips BJ, Price EM, Curran EM, Laughlin MH. Regulation of nitric oxide-dependent vasodilation in coronary arteries of estrogen receptor-alpha-deficient mice. Am J Physiol Heart Circ Physiol. 2003 Nov;285(5):H2150-7. Epub 2003 Jul 24.</citation>
    <PMID>12881205</PMID>
  </reference>
  <reference>
    <citation>Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Sinopoli F, Mattioli PL. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes. 2001 Jan;50(1):159-65.</citation>
    <PMID>11147782</PMID>
  </reference>
  <reference>
    <citation>Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, Green DJ. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H2-12. doi: 10.1152/ajpheart.00471.2010. Epub 2010 Oct 15. Review.</citation>
    <PMID>20952670</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>Karen Birch</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>flow mediated dilation</keyword>
  <keyword>lipid profile</keyword>
  <keyword>blood pressure</keyword>
  <keyword>flavanones</keyword>
  <keyword>Caucasian</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03611114/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03611114/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

